Felzartamab in AMR (2024) — Trial Summary

Felzartamab in AMR (2024): This phase 2, double-blind, randomized, placebo-controlled trial evaluated felzartamab, a CD38 monoclonal antibody, in kidney transplant recipients with late antibody-mediated rejection (AMR) occurring at least 180 days after transplantation.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.